Carter Todd Alfred 4

What Happened Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics (VYGR), sold 3,525 shares of common stock on Feb 10, 2026. The sale was reported at a weighted average price of $3.85 per share for total proceeds of approximately $13,571. This was a sale (not a purchase) and—per the filing—was executed to satisfy tax withholding associated with the vesting of restricted stock units (RSUs), not a discretionary trade by the insider.

Key Details

• Transaction date: 2026-02-10 (Form 4 filed 2026-02-11; no late filing indicated).
• Shares sold: 3,525; weighted average price: $3.85; total proceeds: ~$13,571.
• Price range: shares were sold in multiple transactions at prices between $3.71 and $3.91.
• Reason/footnote: Sold pursuant to a durable automatic sales instruction as a sell-to-cover to satisfy tax withholding on RSUs that vested Feb 9, 2026 (not discretionary).
• Shares owned after transaction: Not reported in this Form 4.
• Reporting/footnote offer: The filer can provide a breakdown of the number of shares sold at each price on request to the company or SEC staff.

Context This was a routine sell-to-cover tied to RSU vesting—common for insiders when shares vest and taxes are due. Such transactions are typically administrative and do not necessarily indicate a change in the insider’s view of the company.